An update on the toxicity of Aβ in Alzheimer’s disease

Jürgen Götz 1
Lars M Ittner 1
Nicole Schonrock 1
Roberto Cappai 2

1 Alzheimer’s and Parkinson’s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, NSW, Australia; 2 Department of Pathology, The University of Melbourne, Victoria, Australia

Abstract: Alzheimer’s disease is characterized histopathologically by deposition of insoluble forms of the peptide Aβ and the protein tau in brain. Aβ is the principal component of amyloid plaques and tau of neurofibrillary tangles. Familial cases of AD are associated with causal mutations in the gene encoding the amyloid precursor protein, APP, from which the amyloidogenic Aβ peptide is derived, and this supports a role for Aβ in disease. Aβ can promote tau pathology and at the same time its toxicity is also tau-dependent. Aβ can adopt different conformations including soluble oligomers and insoluble fibrillar species present in plaques. We discuss which of these conformations exert toxicity, highlight molecular pathways involved and discuss what has been learned by applying functional genomics.

Keywords: amyloid, mitochondria, oligomer, proteomic, tau, transgenic

Incidence of dementia

Alzheimer’s disease (AD) is the most common cause of dementia, comprising 50%–70% of all cases and affecting more than 15 million people worldwide. Frontotemporal dementia (FTD), in comparison, is less common but may make up to 50% of dementia cases presenting before the age of 60 (Graff-Radford and Woodruff 2007). Dementia is defined as the significant loss of intellectual abilities such as memory functions, severe enough to interfere with social or occupational functioning. At present, AD cannot be cured which is different from memory dysfunction caused by malnutrition, drug abuse or depression where some form of treatment is available (Patel et al 2007).

Neuropathology of AD and FTD

The AD brain is characterized by massive neuronal cell and synapse loss at specific predilection sites (Selkoe 2002). The extracellular plaques and the intracellular neurofibrillary tangles are the key histopathological hallmarks of AD. The major proteinaceous component of the amyloid plaques is a 40- to 42-amino acid polypeptide termed Aβ (Aβ40 and Aβ42), which is derived by proteolytic cleavage from the amyloid precursor protein, APP, as part of normal cellular metabolism (Glenner and Wong 1984; Masters et al 1985). β-Secretase is the protease that generates the amino terminus of Aβ and γ-secretase cleavage at the carboxy-terminus dictates its length. Aβ40 is the most common species and Aβ42 is the more fibrillogenic and neurotoxic species. Recent evidence suggests that Aβ40 may prevent Aβ42 from aggregating and forming plaques (Yan and Wang 2007). β-Secretase activity has been attributed to a single protein, BACE 1 (Vassar et al 1999), whereas γ-secretase activity depends on four components, presenilin, nicastrin, APH-1 and PEN-2 forming a proteolytic complex (Edbauer et al 2003). α-Secretase is involved in the non-amyloidogenic pathway by cleaving APP within the Aβ domain, thus precluding Aβ formation (Gotz and Ittner 2008). Which higher order forms of Aβ exert toxicity is a matter of debate. The conflicting data as well as putative mechanisms of toxicity are discussed in detail below.
The second histopathological hallmark of AD are the neurofibrillary lesions that are found in cell bodies and apical dendrites as neurofibrillary tangles, in distal dendrites as neuropil threads, and in the abnormal neurites that are associated with some β-amyloid plaques (neuritic plaques). Neurofibrillary tangles are also abundant, in the absence of overt plaques, in FTD and other so-called tauopathies (Lee et al 2001). The neurofibrillary lesions contain aggregates of the microtubule-associated protein tau that under physiological conditions is mainly localized to the axonal compartment of neurons (Goedert et al 1988). In tauopathies such as PSP (Progressive Supranuclear Palsy) or CBD (Corticobasal Degeneration), tau also forms aggregates in non-neuronal cells (Gotz 2001), emphasizing the important role of glia in disease (Kurosiński and Gotz 2002). Tau has an unusually high content of serine and threonine residues and many of these are phosphorylated under physiological conditions (Chen et al 2004a). Under pathological conditions, tau is hyperphosphorylated, which means that it is phosphorylated to a higher degree at physiological sites, and at additional “pathological” sites. Phosphorylation tends to dissociate tau from microtubules. Tau also undergoes a conformational change which likely assists in differential phosphorylation (Jicha et al 1997). Both tau and Aβ undergo nucleation-dependent fibril formation (Harper and Lansbury 1997). In the course of this process, initially dispersed polypeptide chains slowly come together to form a diverse array of fibrillation nuclei that enable the rapid outgrowth into higher order assemblies including fibrils (Hortschansky et al 2005; Pellarin and Caflisch 2006; Gotz et al 2008).

Genetics of AD and FTD
In familial AD, autosomal dominant mutations have been identified in three genes: APP and the presenilin 1 (PS1) and presenilin 2 (PS2) genes. Together, they account for less than 1% of the total number of AD cases (Delacourte et al 2002). In addition, several susceptibility genes have been identified but only the apolipoprotein E (APOE) gene has been unanimously confirmed and found to be associated with sporadic AD (Rocchi et al 2003). Clinically and histopathologically, early-onset familial AD cannot be discriminated from late-onset sporadic AD (Gotz 2001).

Whereas in AD no mutations were found in the MAPT gene encoding tau, they were identified in FTD with Parkinsonism linked to chromosome 17 (FTDP-17) (Hutton et al 1998; Poorkaj et al 1998; Spillantini et al 1998). This established that dysfunction of tau in itself can cause neurodegeneration and lead to dementia. The existence of a subgroup of FTD with no tau aggregation was enigmatic for some time leading to the coining of terms such as ‘dementia lacking distinctive histology’. This dementia with tau-negative and ubiquitin-positive lesions today is termed FTLD-U or FTDU-17 although this is misleading as it implies that the tau lesions in FTDP-17 are ubiquitin-negative which is not the case.

FTDU-17 is caused by loss-of-function mutations in the gene encoding progranulin (GRN), a growth factor involved in multiple physiological and pathological processes including tumorigenesis (Baker et al 2006; Cruts et al 2006). The TAR DNA-binding protein of 43 kDa (TDP-43) is a constituent of the ubiquitin-positive inclusions in both FTLD-U and sporadic amyotrophic lateral sclerosis (ALS) arguing for an overlap in the pathology between these two entities (Neumann et al 2006). Similar to tau, in diseased brain, TDP-43 becomes hyperphosphorylated, ubiquitinated, and carboxy-terminally truncated. Mutations in the gene encoding valosin-containing protein cause frontotemporal dementia with inclusion body myopathy and Paget disease of bone (IBMPFD), a rare, autosomal-dominant disorder. As TDP-43, but not valosin-containing protein, is accumulating in the ubiquitin-positive inclusions in IBMPFD this would argue that valosin-containing protein gene mutations lead to a dominant negative loss or alteration of valosin-containing protein function culminating in impaired degradation of TDP-43. In other words, TDP-43 is a common pathologic substrate linking a variety of distinct patterns of FTLD-U pathology caused by different genetic alterations (Neumann et al 2007).

Clinical features of AD and FTD
AD is characterized by early memory deficits, followed by a gradual erosion of other cognitive functions such as judgment, verbal fluency and orientation. The most severe neuropsychopathological changes occur in the hippocampal formation, followed by the association cortices and subcortical structures, including the amygdala and the nucleus basalis of Meynert (Arnold et al 1991). Neurofibrillary tangles develop and spread in a predictable manner across the brain providing the basis for distinguishing six stages of disease progression: the transentorhinal Braak stages I-II represent clinically silent cases; the limbic stages III-IV incipient AD; and the neocortical stages V-VI fully developed AD. By using phosphorylation-dependent anti-tau antibodies such as AT8, neuronal changes can be visualized well before the actual formation of neurofibrillary tangles (Braak and Braak 1991, 1995).

In contrast to AD, which is characterized predominantly by memory loss, FTD is mainly initiated with behavioral
impairment. The average age of diagnosis is about 60, which is around 10 years before the average sporadic AD patient is diagnosed (Snowden et al 2001; Weder et al 2007). Patients may have an often asymmetrical atrophy of the frontal and temporal cortex. There is evidence that motor neuron disease and FTD coexist, and the motor symptoms may precede, coincide, or follow the development of cognitive and behavioral changes (Graff-Radford and Woodruff 2007). In a significant subset of FTD, late parkinsonism is found (Lee et al 2001).

Animal models of AD and FTD
To better understand the role of Aβ and tau in AD and related disorders, experimental animal models have been developed which reproduce aspects of the neuropathological characteristics of these diseases (Gotz et al 2007; Gotz and Ittner 2008).

In 1995, Games and coworkers established the first Aβ plaque-forming mouse model by targeting high levels of the disease-linked V717F mutant form of APP in brain, using the platelet-derived growth factor mini-promoter for expression. These PDAPP mice showed many of the pathological features of AD, including extensive deposition of extracellular amyloid plaques, astrocytosis and neuritic pathological features of AD, including extensive deposition of tau and neurofibrillary tangles (Games et al 1995). Similar features were observed in a second transgenic model established by Hsiao and coworkers by expressing the APPsw mutation inserted into a hamster prion protein cosmid vector (Hsiao et al 1996). The APP23 strain was established by expressing APPsw under the control of the neuronal mThy1.2 promoter, with a seven-fold overexpression of APP (Sturchler-Pierrat et al 1997; Stalder et al 1999). Subsequently, many more models have been developed such as the TgCRND8 or J20 mice (Janus et al 2000; Mucke et al 2000). These mouse models have been instrumental in addressing aspects of Aβ toxicity and testing therapies such as vaccination trials (Gotz 2001; Gotz et al 2004b; Kulic et al 2006).

The first tau transgenic model was established by us in 1995, expressing the longest human brain tau isoform, without a pathogenic mutation, in mice using the hThy1 promoter for neuronal expression (Gotz et al 1995). Despite the lack of neurofibrillary pathology, these mice modeled aspects of human AD, such as the somatodendritic localization of hyperphosphorylated tau and, therefore, represented an early ‘pre-tangle’ phenotype. The subsequent use of stronger promoters caused a more pronounced tau phenotype in transgenic mice (Ishihara et al 1999; Spittaels et al 1999; Probst et al 2000; Gotz and Nitsch 2001). Once the first pathogenic FTDP-17 mutations were identified in the MAPT gene in 1998, several groups expressed them in mice and achieved neurofibrillary tangle formation, both in neurons and in glial cells (Gotz and Ittner 2008). We, for example, expressed G272V and P301L mutant tau and obtained mice with aggregated tau and neurofibrillary tangles (Gotz et al 2001a; Gotz et al 2001b; Gotz et al 2001c; Deters et al 2008). The P301L tau-expressing pR5 mice showed a behavioural impairment in amygdala- and hippocampus-dependent tasks; aspects of the behavioral impairment could be correlated with the aggregation pattern of the transgene (Pennanen et al 2004; Pennanen et al 2006). K369I transgenic mice, on the other hand, model Parkinsonism in FTD, in parts owing to expression of the transgene in the substantia nigra (Ittner et al 2008).

Cross-talk between Aβ and tau
The amyloid cascade hypothesis claims, in simplistic terms, that in the pathogenic cascade of AD, Aβ is upstream of tau (Hardy and Selkoe 2002). To address the interaction between Aβ and tau (Gotz et al 2004a), Aβ plaque-forming Tg2576 mice were crossed with tangle-forming P301L tau-transgenic JNPL3 mice; also, P301L tau transgenic pR5 mice were intracerebrally injected with fibrillar preparations of Aβ42 (Gotz et al 2001b; Lewis et al 2001). Both strategies caused an increased tau phosphorylation at pathological epitopes and neurofibrillary tangle formation, establishing a link between Aβ and tau in vivo (Gotz et al 2001b; Lewis et al 2001). Similarly, tangle formation was aggravated by infusing brain extracts of aged plaque-forming APP23 mice intracerebrally in P301L tau transgenic mice or by crossing APP23 and P301L tau transgenic mice (Bolmont et al 2007). Together, these studies established that Aβ exaggerates a pre-existing tau pathology supporting, at least in parts, the amyloid cascade hypothesis in mice.

Interestingly, recent evidence suggests that Aβ toxicity is also tau-dependent (Roberson et al 2007). Reducing endogenous tau levels prevented behavioral deficits as assessed in the Morris water maze, without altering Aβ levels. This was achieved by crossing plaque-forming APP transgenic mice onto hetero- and homozygous tau knockout backgrounds (Roberson et al 2007). Tau reduction also protected both transgenic and non-transgenic mice against pentylenetetrazole (PTZ)-mediated excitotoxicity as shown by dramatic changes in seizure severity and latency. We were able to reproduce these findings in a second plaque-forming APP transgenic mouse model (Ittner et al submitted). Earlier findings in cultured hippocampal neurons derived from tau
knockout and transgenic mice supports the model that tau is required for Aβ toxicity (Rapport et al 2002). Together, this suggests that a reduction in tau levels is a potentially powerful treatment strategy for AD and other neurological conditions that are associated with neurotoxicity. A mechanistic explanation is lacking and therefore the importance of this information should encourage more research groups to work on the interaction between Aβ and tau.

**Functional genomics and Aβ toxicity**

An unbiased approach to address the toxicity of tau and Aβ is by functional genomics, which encompasses transcriptomic and proteomic techniques (Chen et al 2004b; Hoerndli et al 2004; David et al 2005a; Hoerndli et al 2005). These highlighted a role for oxidative stress (see below) and impaired axonal transport in disease (Gotz et al 2006). When we analyzed the proteome pattern of total brain from P301L tau transgenic pR5 and wild-type mice by proteomics, we discovered that it was mainly metabolic related proteins including mitochondrial respiratory chain complex components, antioxidant enzymes and synaptic proteins that were modified in P301L tau mice. Importantly, mitochondrial dysfunction could be functionally validated in the P301L tau mice. Furthermore, the reduction in mitochondrial complex V levels in the P301L tau mice was also decreased in human P301L FTDP-17 brains. Finally, P301L tau mitochondria displayed an increased vulnerability towards fibrillar preparations of Aβ42, suggesting a synergistic action of tau and Aβ pathology on the mitochondria (David et al 2005b).

In a follow-up study we investigated the toxicity of oligomeric Aβ species that in recent years have been suggested to be the main culprit, rather than fibrillar Aβ (Hartley et al 1999; Necula et al 2007). The identity of the Aβ toxic species in both AD brains and in experimentally generated systems correlates best with the soluble, rather than the insoluble fibrillar forms. However, at present, there is little chemical and structural detail at the molecular and atomic level about the various aggregates to properly define the toxic species (Cappai and Barnham 2008). Interestingly, in cortical brain cells obtained from P301L tau transgenic pR5 mice both oligomeric and fibrillar, but not monomeric Aβ42, caused a decreased mitochondrial membrane potential (Eckert et al 2008a). This was not observed with cerebellar preparations indicating selective vulnerability of cortical neurons. Furthermore, we measured reductions in state 3 respiration, the respiratory control ratio and uncoupled respiration when incubating P301L tau mitochondria either with oligomeric or fibrillar preparations of Aβ42. We also found that aging specifically increased the sensitivity of mitochondria to oligomeric Aβ42 damage indicating that while oligomeric and fibrillar Aβ42 are both toxic, they exert different degrees of toxicity in mitochondria from older animals (Eckert et al 2008a).

To understand which processes are disrupted by Aβ42 in the presence of tau aggregates a comparative proteomics study was performed in both a cellular and an in vivo system (David et al 2006). P301L tau expressing neuroblastoma cells were treated with Aβ42 as prior studies had shown that this caused tau filament formation (Ferrari et al 2003; Pennanen and Gotz 2005). In parallel, the amygdala of P301L tau transgenic mice was stereotaxically injected with Aβ42 as this causes increased tangle formation (Gotz et al 2001b). When the deregulated proteins in the two experimental paradigms were classified, it was found that a significant fraction of the altered proteins belonged to the same functional categories, i.e., stress response and metabolism. We also identified model-specific effects of Aβ42 treatment such as differences in cell signaling proteins in the cellular model and changes in cytoskeletal and synapse proteins in the amygdala. By Western blotting and immunohistochemistry, we were able to show that 72% of the tested candidates were altered in human AD brain with a major emphasis on stress-related unfolded protein responsive candidates. This highlights these processes as important initiators in the Aβ-mediated pathogenic cascade in AD and further supports the role of unfolded proteins in the course of AD (David et al 2006).

Human SH-SY5Y neuroblastoma cells were also investigated by transcriptomics to assess the role of P301L mutant tau expression and treatment with or without Aβ on gene regulation. We found that Aβ and P301L tau expression independently affected the regulation of genes controlling cell proliferation and synaptic elements. Moreover, Aβ and P301L tau acted synergistically on cell cycle and DNA damage genes, yet influenced specific genes within these categories. By using neuronally differentiated P301L tau cells, it was shown that Aβ treatment induced an early up-regulation of cell cycle control and synaptic genes. Together, the study showed that Aβ treatment and human tau over-expression in a cell culture model acted synergistically to promote aberrant cell cycle re-entry supporting the mitosis failure hypothesis in AD (Arendt 2003; Hoerndli et al 2007).

**The Yin and Yang of Aβ**

AD has been termed a synaptic failure (Selkoe 2002). While Aβ can kill neurons, it can also act by causing synaptotoxicity...
which may be more relevant for the earlier stages of AD that are best characterized by synaptic loss rather than neuronal death. Loss of synaptic terminals or dendritic spines could cause the associated decline in cognitive functions that characterizes AD. Whether the neurotoxic and synaptotoxic actions of Aβ are separate activities or whether they share common mechanisms is not known (Cappai and Barnham 2008).

How cells respond to Aβ varies depending upon the concentration of Aβ used, which adds another level of complexity. While Aβ peptide added at micromolar concentrations to primary neuronal cultures induces cell death (Yankner et al 1990), low, subnanomolar concentrations are neurotrophic arguing in favor of a physiological function of Aβ (Yankner et al 1990). As discussed above, the neurotoxic activity of Aβ is dependent upon its aggregation state. When Aβ aggregation was induced this increased its neurotoxic activity suggesting that the toxic species was associated with the formation of fibrils (Pike et al 1991a; Pike et al 1991b; Pike et al 1993). At present, however, there is a major research focus on the role of non-fibrillar soluble Aβ as the toxic species in AD (Lambert et al 1998; Walsh et al 2002; Smith et al 2007). These species have been given different names, including Aβ-derived diffusible ligands (ADDLs) (Lambert et al 1998), globulomers (Barghorn et al 2005) and the Aβ star species 56 (Aβ*56) (Lesne et al 2006). To assist in identifying these species, conformational antibodies have been developed that not only stabilize the Aβ protofibrils but also prevent mature amyloid fibril formation (Habicht et al 2007).

Aβ can inhibit long-term potentiation (LTP), a model system for synaptic strengthening and memory (Lambert et al 1998; Walsh et al 2002; Cleary et al 2005; Klyubin et al 2005; Trommer et al 2005). When cell medium containing abundant Aβ monomers and proposed oligomers, but not amyloid fibrils was microinjected into rat brain, this markedly inhibits hippocampal long-term potentiation (LTP) (Walsh et al 2002). Immunodepletion from the medium of all Aβ species completely abrogated this effect. Pretreatment of the medium with insulin-degrading enzyme, which degrades Aβ monomers but not oligomers, did not prevent the inhibition of LTP, indicating a role for Aβ oligomers. These were shown to disrupt synaptic plasticity in vivo at concentrations found in human brain and cerebrospinal fluid, in the absence of monomeric or fibrillar amyloid. When cells were treated with γ-secretase inhibitors at doses which prevented oligomer formation but allowed appreciable monomer production, this no longer disrupted LTP, indicating that synaptotoxic Aβ oligomers can be targeted therapeutically (Walsh et al 2002; Walsh et al 2005).

In Neuro-2A cells, oligomers were shown to induce a tenfold greater increase in neurotoxicity as compared to fibrils (Stine et al 2003). However, whereas LTP seems to be inhibited by oligomeric Aβ only and not fibrillar Aβ, in a different experimental paradigm, the two species seem to have both toxic, yet diverse effects (White et al 2005). Using rat astrocyte cultures, oligomeric Aβ12 was shown to induce initial high levels of the pro-inflammatory molecule IL-1β that decreased over time, whereas fibrillar Aβ caused increased levels over time (White et al 2005). It has been suggested that their neurotoxic activity is associated with dimeric and trimeric species however the exact composition of these higher molecular weight Aβ species has not been determined (Walsh et al 2002; Cleary et al 2005) and remains a crucial point to definitively establish their molecular identity. Together, this shows that the relative role of the toxicity of monomeric compared to oligomeric compared to fibrillar species is far from being resolved.

**Aβ and downstream signaling**

What are the downstream effectors of Aβ toxicity? Aβ may act via a plethora of pathways to induce synaptic and neuronal degeneration (Small et al 2001). Aβ’s anti-LTP activity can be modulated with antagonists to the p38 MAP kinase (Wang et al 2004) and the Jun NH2-terminal kinase (JNK) pathways (Minogue et al 2003), both of which have also been implicated in tau phosphorylation (Kins et al 2001; Kins et al 2003). While inhibitors of p38, JNK, GSK-3β and phosphatidylinositol 3-kinase showed either no or only minor inhibition of Aβ oligomer-mediated cell death in mouse hippocampal slices, inhibitors of MAPK kinase kinase, which is upstream of the extracellular signal-regulated kinases, significantly inhibited Aβ-mediated neuronal death (Chong et al 2006).

Another interesting kinase is the non-receptor tyrosine kinase Fyn, as it links Aβ and tau. Fyn is a known interaction partner of tau (Lee et al 1998). Furthermore, Fyn is necessary for the toxicity of ADDLs (an oligomeric form of Aβ) as Fyn knockout neurons are resistant to ADDL-mediated neuronal cell death (Lambert et al 1998). Moreover, Fyn knockout mice display reduced synaptotoxicity without affecting aberrant sprouting, when crossed with APP transgenic mice (Chin et al 2004). Fyn has a role in modulating synaptic activity and plasticity, by phosphorylating the NMDA receptor (Braithwaite et al 2006). This finding is consistent with the fact that Aβ oligomers alter the transport of the NMDA receptor by promoting its endocytosis and resulting in decreased NMDA receptor activity both
in vitro and in APP transgenic mice (Snyder et al 2005). Work in neuronal and astrocyte cultures further suggests that Aβ causes Ca2+-dependent oxidative stress by activating an astrocytic NADPH oxidase, with neuronal death following through a failure of antioxidant support (Abramov et al 2004). Together, this suggests a fine-balanced network of molecular interactions (Cappai and Barnham 2008).

At present it is not understood whether Aβ acts via a receptor or whether membrane binding alone is sufficient (Cappai and Barnham 2008). If Aβ acts via a receptor, this receptor may have specificity for Aβ or it may bind proteins or peptides with shared amyloid properties. Work in primary cortical and hippocampal cultures treated with Aβ and human amylin, respectively, indicates that the latter may be the case, as rat amylin, which is not amyloidogenic, turns out not to be toxic (Lim et al 2008). Membrane interaction of Aβ can occur via its hydrophobic carboxy-terminal domain (Bhatia et al 2000; Ambroggio et al 2005) or by electrostatic interactions mediated by the charged amino acids in the amino-terminal domain (Lau et al 2006). Aβ may bind to the cell membrane forming channels or pores that disrupt ion homeostasis, hence leading to neuronal dysfunction (Arispe et al 1993; Pollard et al 1995; Holscher 1998; Bhatia et al 2000; Lin et al 2001). As several molecules associated with disease (such as the Prion protein, the British peptide, or human amylin) can form soluble oligomers and bind to membranes and disrupt ion homeostasis, this may be an inherent property of amyloidogenic proteins or peptides (Demuro et al 2005).

### Aβ binding proteins

A number of Aβ-binding proteins have been identified on the plasma membrane of neurons and glial cells. These include the alpha7 nicotinic acetylcholine receptor, the receptor for advanced glycosylation end-products (RAGE), APP itself, the NMDA receptor, the P75 neurotrophin receptor (P75NTR), the scavenger receptors, CD36 and low-density lipoprotein receptor-related protein (LRP) members (Verdier et al 2004). RAGE can bind both non-fibrillar and fibrillar forms of Aβ (Yan et al 1996). Transgenic mice co-expressing mutant APP and RAGE revealed an earlier onset of memory defects and synaptic dysfunction than single APP transgenic mice (Arancio et al 2004). LRP, apoE and the serum protein α2-macroglobulin (α2M) probably modulate Aβ toxicity via clearance of apoE:Aβ and α2M:Aβ complexes or Aβ alone from the brain and hence reduce Aβ levels (Shibata et al 2000; Deane et al 2004). The addition of an anti-NMDA receptor antibody can block Aβ oligomer binding to neurons and reduce ROS stimulation in hippocampal cultures (De Felice et al 2007) suggesting a direct interaction between these two proteins. Alternatively, Aβ may be interacting with NMDA receptor via an integrin-mediated effect (Bi et al 2002). P75NTR can bind a variety of Aβ oligomeric species and modulate Aβ toxicity in a cell type- and P75 isoform-dependent manner (Coulson 2006; Sotthibundhu et al 2008). Full-length P75NTR blocks toxicity of fibrillar and non-fibrillar Aβ in primary neurons (Zhang et al 2003), but promotes toxicity of fibrillar Aβ in neuroblastoma cells (Perini et al 2002).

Aβ may not only bind to the cell surface but also act on intracellular organelles such as mitochondria (Lustbader et al 2004; Caspersen et al 2005; Crouch et al 2005; Devi et al 2006; Manczak et al 2006) whose function it impairs (Keil et al 2004; David et al 2005b; Eckert et al 2008a; Eckert et al 2008b). Mitochondrial dysfunction was also linked to full-length and carboxy-terminally truncated APP, that was shown to accumulate exclusively in the protein import channels of mitochondria of human AD, but not age-matched control brains (Devi et al 2006). Similarly, accumulation of full-length APP in the mitochondrial compartment in a transmembrane-arrested form, but not lacking the acidic domain, was shown to cause mitochondrial dysfunction and impair energy metabolism (Anandatheerthavarada et al 2003). Aβ can disrupt mitochondrial cytochrome c oxidase activity (Crouch et al 2005; Takuma et al 2005) in a sequence- and conformer-dependent manner (Crouch et al 2005). The Aβ binding protein alcohol dehydrogenase (ABAD) is a short-chain alcohol dehydrogenase that binds to Aβ in the mitochondrial matrix. This lead to mitochondrial failure via changes in mitochondrial membrane permeability and a reduction in the activities of enzymes involved in mitochondrial respiration (Lustbader et al 2004). ABAD can bind to the oligomeric Aβ1-42 present in the cortical mitochondria of APP transgenic mice (Yan et al 2007). Protease sensitivity assays suggest that Aβ gains access to the mitochondrial matrix rather than simply being adsorbed to the external surface of mitochondria (Caspersen et al 2005). The interaction between Aβ and the mitochondria may explain how Aβ induces apoptosis and caspase activation (Ivins et al 1998; White et al 2001; Lustbader et al 2004). Intracellular Aβ may be derived from internalized extracellular Aβ or from intracellularly generated Aβ (Casas et al 2004; Gomez-Ramos and Asuncion Moran 2007; Wegiel et al 2007). The presence of intracellular Aβ adds a further level of complexity to the mechanism of Aβ toxicity as this enables direct access to organelles that are vital for the function and viability of neurons. It is needless to say, that this has important implications for treatment strategies.
Conclusions
What can be expected in the forthcoming years? Some of the current therapeutic trials targeting Aβ may come to fruition (Gotz and Ittner 2008). With the advent of new tools it will likely become easier to discriminate Aβ conformations and hence allow establishing a defined role of specific conformers in toxicity (Habicht et al 2007). The mode of Aβ uptake and/or binding by neurons and other cell types will be elucidated and interacting proteins, both under physiologic and pathologic conditions, will be identified. Finally, how Aβ and tau interact and contribute to disease will assist in the development of treatment strategies for AD and related disorders.

Acknowledgments
JG is a Medical Foundation Fellow and has been supported by the University of Sydney, the National Health and Medical Research Council (NHMRC), the Australian Research Council (ARC), the New South Wales Government through the Ministry for Science and Medical Research (BioFirst Program), the Nerve Research Foundation, the Medical Foundation (University of Sydney) and the Judith Jane Mason and Harold Stannett Williams Memorial Foundation.

Disclosures
The authors have no conflicts of interest to disclose.

References
Abramow AJ, Canevari L, Duchen MR. 2004. Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture. Biochim Biophys Acta, 1742:81–7.
Ambroggio EE, Kim DH, Separovic F, et al. 2005. Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1–42: a membrane-disrupting peptide. Biophys J, 88:2706–13.
Anandatheerthavarada HK, Biswas G, Robin MA, et al. 2003. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol, 161:41–54.
Arancio O, Zhang HP, Chen X, et al. 2004. RAGE potentials Abeta-induced perturbation of neuronal function in transgenic mice. Embo J, 23:4096–105.
Arendt T. 2003. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the ‘Dr Jekyll and Mr. Hyde concept’ of Alzheimer’s disease or the yin and yang of neuroplasticity. Prog Neurobiol, 71:83–248.
Arisz N, Rojas E, Pollard HB. 1993. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A, 90:567–71.
Arnold SE, Hyman BT, Flory J, et al. 1991. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex, 1:103–16.
Baker M, Mackenzie IR, Pickering-Brown SM, et al. 2006. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 442:916–9.
Barghorn S, Nimurich V, Stiebinger A, et al. 2005. Globular amyloid beta-peptide oligomer – a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem, 95:834–47.
Bhatia R, Lin H, Lal R. 2000. Fresh and globular amyloid beta protein (1–42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. Faseb J, 14:1233–43.
Bi X, Gall CM, Zhou J, et al. 2002. Uptake and pathogenic effects of amyloid beta peptide 1–42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience, 112:827–40.
Bolmont T, Clavaguera F, Meyer-Luehmann M, et al. 2007. Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol, 171:2012–20.
Braak H, and Braak E. 1991. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl), 82:239–59.
Braak H, Braak E. 1995. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging, 16:271–8; discussion 8–84.
Braithwaite SP, Paul S, Nairn AC, et al. 2006. Synaptic plasticity: one STEP at a time. Trends Neurosci, 29:452–8.
Cappai R, and Barnham KJ. 2008. Delineating the mechanism of Alzheimer’s disease A beta peptide neurotoxicity. Neurochem Res, 33:526–32.
Casas C, Sergeant N, Irier JM, et al. 2004. Massive CA1/2 neuronal loss with intraneuronal A/Terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol, 165:1289–300.
Caspersen C, Wang N, Yao I, et al. 2005. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. Faseb J, 19:2040–1.
Chen F, David D, Ferrari A, et al. 2004a. Posttranslational modifications of tau - Role in human tauopathies and modeling in transgenic animals. Curr Drug Targets, 5:503–15.
Chen F, Wollmer MA, Hoerndli F, et al. 2004b. Role for glyoxalase I in Alzheimer’s disease. Proc Natl Acad Sci U S A, 101:7687–92.
Chin J, Palop JJ, Yu GQ, et al. 2004. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci, 24:4692–7.
Chong YH, Shin YJ, Lee EO, et al. 2006. ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem, 281:20315–25.
Cleary JP, Walsh DM, Hofmeister JJ, et al. 2005. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci, 8:79–84.
Coulsdon EJ 2006. Does the p 75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer’s disease? J Neurochem, 98:654–60.
Crouch PJ, Blake R, Duce JA, et al. 2005. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta 1–42. J Neurosci, 25:672–9.
Cruts M, Gijselinck I, van der Zee J, et al. 2006. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 442:920–4.
David D, Hoerndli F, Gotz J. 2005a. Functional Genomics meets neurodegenerative disorders Part I: Transcriptomic and proteomic technology. Prog Neurobiol, 76:153–68.
David DC, Hauptmann S, Scherping I, et al. 2005b. Proteomic and functional analysis reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem, 280:23802–14.
David DC, Ittner LM, Gehrig P, et al. 2006. β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer’s disease models reveals similar deregulated cellular processes. Proteomics, 6:6566–77.
De Felice FG, Velasco PT, Lambert MP, et al. 2007. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem, 282:11590–601.
Deane R, Wu Z, Sagare A, et al. 2004. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron, 43:333–44.
Delacourte A, Sergeant N, Champain D, et al. 2002. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease. *Neurology*, 59:398–407.

Demuro A, Mina E, Kayed R, et al. 2005. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. *J Biol Chem*, 280:17294–300.

Deters N, Ittner LM, and Gotz J. 2008. Divergent phosphorylation pattern of tau in P301L tau transgenic mice. *Eur J Neurosci*, 28:137–47.

Devi L, Prabhu BM, Galati DF, et al. 2006. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. *J Neurosci*, 26:9057–68.

Eckert A, Droe S, Brandt U, et al. 2008a. Oligomeric and fibrillar species of β-amyloid (Aβ) both impair mitochondrial function in P301L tau transgenic mice. *J Mol Med*, 86:1255–67.

Eckert A, Hauptmann S, Scherping I, et al. 2008b. Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. *Neurogener Dis*, 5:157–9.

Edbauer D, Winkler E, Regula JT, et al. 2003. Reconstitution of a novel cerebrovascular amyloid protein. *Biochim Biophys Res Commun*, 120:885–90.

Goedert M, Wischik CM, Crowther RA, et al. 1988. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of the cDNA encoding a microtubule-associated protein tau. *Proc Natl Acad Sci U S A*, 85:4051–5.

Gomez-Ramos P, and Asuncion Moran M. 2007. Ultrastructural localization of intraneuronal Abeta-peptide in Alzheimer disease brains. *J Alzheimers Dis*, 11:53–9.

Gotz J 2001. Tau and transgenic animal models. *Brain Res Brain Res Rev*, 35:266–86.

Gotz J, Chen F, Carmeliet P, et al. 2001a. Tau filament formation in transgenic mice expressing P301L Tau. *J Biol Chem*, 276:529–34.

Gotz J, Chen F, van Dorpe J, et al. 2001b. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta42 fibrils. *Science*, 293:1491–5.

Gotz J, Deters N, Doldissen A, et al. 2007. A decade of tau transgenic animal models and beyond. *Brain Pathol*, 17:91–103.

Gotz J, and Ittner LM. 2008. Animal models of Alzheimer’s disease and frontotemporal dementia. *Nat Rev Neurosci*, 9:532–44.

Gotz J, Ittner LM, Fandrich M, et al. 2008. Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods? *J Alzheimers Dis*, 14:423–9.

Gotz J, Ittner LM, Kins S. 2006. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer’s disease? *J Neurochem*, 98:993–1006.

Gotz J, and Nitsch RM. 2001. Compartimentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice. *Neuroreport*, 12:2007–16.

Gotz J, Probst A, Spillantini MG, et al. 1995. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. *Embo J*, 14:1304–13.

Gotz J, Schild A, Hoerndli F, et al. 2004a. Amyloid-induced neurofibrillary tangle formation in Alzheimer’s disease: insight from transgenic mouse and tissue-culture models. *Int J Dev Neurosci*, 22:453–65.

Gotz J, Streffer JR, David D, et al. 2004b. Transgenic animal models of Alzheimer’s disease and related disorders: Histopathology, behavior and therapy. *Mol Psychiatry*, 9:664–83.

Gotz J, Tolnay M, Barmettler R, et al. 2001c. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. *Eur J Neurosci*, 13:2131–40.

Graff-Radford NR, Woodruff BK. 2007. Frontotemporal dementia. *Semin Neurol*, 27:48–57.

Habicht G, Haupt C, Friedrich RP, et al. 2007. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. *Proc Natl Acad Sci U S A*, 104:19232–7.

Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. *Science*, 297:353–6.

Harper JD, and Lansbury PT, Jr. 1997. Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. *Annu Rev Biochem*, 66:385–407.

Hartley DM, Walsh DM, Ye CP, et al. 1999. Prototritillar intermediates of amyloid-beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. *J Neurosci*, 19:8876–84.

Hoerndli F, David D, Gotz J. 2005. Functional genomics meets neurodegenerative disorders. Part II: Application and data integration. *Prog Neurobiol*, 76:169–88.

Hoerndli FJ, Pelech S, Papassotirosopoulos A, et al. 2007. Abeta treatment and P301L tau expression in an Alzheimer’s disease tissue culture model act synergistically to promote aberrant cell cycle re-entry. *Eur J Neurosci*, 26:66–72.

Hoerndli FJ, Toigo M, Schild A, et al. 2004. Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. *Anal Biochem*, 335:30–41.

Holscher C. 1998. Possible causes of Alzheimer’s disease: amyloid fragments, free radicals, and calcium homeostasis. *Neurobiol Dis*, 5:129–41.

Hortschansky P, Schroechck V, Christopeit T, et al. 2005. The aggregation kinetics of Alzheimer’s beta-amyloid peptide is controlled by stochastic nucleation. *Protein Sci*, 14:1753–9.

Hsiao K, Chapman P, Nilsen S, et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice [see comments]. *Science*, 274:99–102.

Hutton M, London CL, Rizzu P, et al. 1998. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature*, 393:702–5.

Ishihara T, Hong M, Zhang B, et al. 1999. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the human tau isoform. *Neuron*, 24:751–62.

Ittner LM, Fath T, Ke YD, et al. 2008. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. *Proc Natl Acad Sci U S A*, 105:15997–16002.

Ivins KJ, Bui ET, Cotman CW. 1998. Beta-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. *Neurobiol Dis*, 5:365–78.

Janus C, Pearson J, McLaurin J, et al. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. *Nature*, 408:979–82.

Jicha GA, Bowser R, Kazam IG, et al. 1997. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. *J Neurosci Res*, 48:128–32.

Keil U, Bonert A, Marques CA, et al. 2004. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. *J Biol Chem*, 279:50310–20.

Kins S, Cramer A, Evans DR, et al. 2001. Reduced PP2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. *J Biol Chem*, 276:38193–200.

Kins S, Kurosinski P, Nitsch RM, et al. 2003. Activation of the ERK and JNK signaling pathways caused by neuron specific inhibition of PP2A. *J Biol Chem*, 278:40162–8.

Klyubin I, Walsh DM, Lemere CA, et al. 2005. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. *Nat Med*, 11:556–61.

Kingsbury J, Walsh DM, Lemere CA, et al. 2005. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. *Nat Med*, 11:556–61.
Kulic L, Kurosinski P, Chen F, et al. 2006. Active immunization trial in Abeta42-injected P301L tau transgenic mice. Neurobiol Dis, 22:50–6.

Kurosinski P, Gotz J. 2002. Glial cells under physiologic and pathological conditions. Arch Neurol, 59:1524–8.

Lambert MP, Barlow AK, Chromy BA, et al. 1998. Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A, 95:6448–53.

Lau TL, Ambroggio EE, Tew DJ, et al. 2006. Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. J Mol Biol, 356:759–70.

Lee G, Newman ST, Gard DL, et al. 1998. Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci, 111:3167–77.

Lee VM, Goedert M, Trojanowski JQ. 2001. Neurodegenerative tauopathies. Annu Rev Neurosci, 24:1121–59.

Lesne S, Koh MT, Kotilinek L, et al. 2006. A specific amyloid-beta-protein assembly in the brain impairs memory. Nature, 440:352–7.

Lewis J, Dickson DW, Lin W-L, et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science, 293:1487–91.

Lim YA, Ittner LM, Lim YL, et al. 2008. Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS Lett, 582:2188–94.

Lin H, Bhatia R, Lal R. 2001. Amyloid beta protein forms ion channels: implications for Alzheimer’s disease pathophysiology. Faseb J, 15:2433–44.

Lustbader JW, Cirilli M, Lin C, et al. 2004. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science, 304:448–52.

Manzak M, Anekonda TS, Henson E, et al. 2006. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet, 15:1437–49.

Masters CL, Simms G, Weinman NA, et al. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A, 82:4245–9.

Minogue AM, Schmid AW, Fogarty MP, et al. 2003. Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-beta on long term potentiation and cell death in hippocampus: a role for interleukin-1beta? J Biol Chem, 278:2791–80.

Mucke L, Maslih E, Yu GQ, et al. 2000. High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci, 20:4050–8.

Necula M, Csillik V, Politi V, et al. 2002. Role of p 75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. J Exp Med, 195:907–18.

Neumann M, Mackenzie IR, Cairns NJ, et al. 1993. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci, 13:1676–87.

Pike CJ, Walencwicz AJ, Glabe CG, et al. 1991a. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmocol, 207:367–8.

Rapport M, Dawson HN, Binder LI, et al. 2002. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A, 99:6364–9.

Roberson ED, Searce-Levie K, Palop JJ, et al. 2007. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science, 316:750–4.

Selkoe DJ. 2002. Alzheimer’s disease is a synaptic failure. Science, 298:789–91.

Shibata M, Yamada S, Kumar SR, et al. 2000. Clearance of Alzheimer’s amyloid-beta(1–40) peptide from brain by LDL receptor-related protein 1 at the blood-brain barrier. J Clin Invest, 106:1489–99.

Small DH, Mok SS, Bornstein JC. 2002. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A, 99:6364–9.

Smith DP, Ciccotosto GD, Tew DJ, et al. 2007. Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer’s disease amyloid-beta peptide. Biochemistry, 46:2881–91.

Snowden JS, Batychev D, Varma A, et al. 2001. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry, 70:323–32.

Small DH, Mok SS, Bornstein JC. 2002. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A, 99:6364–9.

Snyder EM, Nong Y, Almeida CG, et al. 2005. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci, 8:1051–8.

Sothibudhanda A, Sykes AM, Fox B, et al. 2008. Beta-amyloid(1–42) induces neuronal death through the p 75 neurotrophin receptor. J Neurosci, 28:3941–6.

Spillantini MG, Murrell JR, Goedert M, et al. 1998. Mutation in the tau gene in familial multiple system atrophy with presenile dementia. Proc Natl Acad Sci U S A, 95:7737–41.

Spittaels K, Van den Haute C, Van Dorpe J, et al. 1999. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol, 155:2153–65.

Stalder M, Phinney A, Probst A, et al. 1999. Association of microglia with amyloid-induced neurotoxicity. Eur J Pharmacol, 360:882–92.

Stine WB, Jr, Dahlgren KN, Krafft GA, et al. 2003. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem, 278:11612–22.

Storchler-Pierrat C, Abramowski D, Duke M, et al. 1997. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A, 94:13287–92.

Takuma K, Yamao A, Huang J, et al. 2005. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. Faseb J, 19:597–8.

Takuma K, Yamao A, Huang J, et al. 2005. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. Faseb J, 19:597–8.

Vassar R, Bennett BD, Babu-Khan S, et al. 1999. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286:735–41.

Neuropsychiatric Disease and Treatment 2008;4(6)
Verdier Y, Zarandi M, Penke B. 2004. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer’s disease. *J Pept Sci*, 10:229–48.

Walsh DM, Klyubin I, Fadeeva JV, et al. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature*, 416:535–9.

Walsh DM, Klyubin I, Shankar GM, et al. 2005. The role of cell-derived oligomers of Abeta in Alzheimer’s disease and avenues for therapeutic intervention. *Biochem Soc Trans*, 33:1087–90.

Wang Q, Walsh DM, Rowan MJ, et al. 2004. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p 38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. *J Neurosci*, 24:3370–8.

Weder ND, Aziz R, Wilkins K, et al. 2007. Fronto-temporal dementias: a review. *Ann Gen Psychiatry*, 6:15.

Wegiel J, Kuchna I, Nowicki K, et al. 2007. Intraneuronal Abeta immuno-reactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. *Acta Neuropathol*, 113:389–402.

White AR, Guirguis R, Brazier MW, et al. 2001. Sublethal concentrations of prion peptide PrP106–126 or the amyloid beta peptide of Alzheimer’s disease activates expression of proapoptotic markers in primary cortical neurons. *Neurobiol Dis*, 8:299–316.

White JA, Manelli AM, Holmberg KH, et al. 2005. Differential effects of oligomeric and fibrillar amyloid-beta 1–42 on astrocyte-mediated inflammation. *Neurobiol Dis*, 18:459–65.

Yan SD, Chen X, Fu J, et al. 1996. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. *Nature*, 382:685–91.

Yan Y, Liu Y, Sorci M, et al. 2007. Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction. *Biochemistry*, 46:1724–31.

Yan Y, and Wang C. 2007. Abeta40 protects non-toxic Abeta42 monomer from aggregation. *J Mol Biol*, 369:909–16.

Yankner BA, Duffy LK, Kirschner DA. 1990. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. *Science*, 250:279–82.

Zhang Y, Hong Y, Bounhar Y, et al. 2003. p 75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. *J Neurosci*, 23:7385–94.